CORCEPT THERAPEUTICS INC's ticker is CORT and the CUSIP is 218352102. A total of 231 filers reported holding CORCEPT THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,932,409 | +71.6% | 401,263 | +40.2% | 0.51% | +75.3% |
| Q2 2023 | $6,369,207 | +2.5% | 286,257 | -0.2% | 0.29% | -4.6% |
| Q1 2023 | $6,213,593 | +3.2% | 286,869 | -3.2% | 0.31% | +0.3% |
| Q4 2022 | $6,018,276 | -40.0% | 296,321 | -24.3% | 0.30% | -44.9% |
| Q3 2022 | $10,032,000 | +23.9% | 391,280 | +14.9% | 0.55% | +30.0% |
| Q2 2022 | $8,097,000 | +2.7% | 340,488 | -2.7% | 0.43% | +17.7% |
| Q1 2022 | $7,882,000 | +13.2% | 349,980 | -0.5% | 0.36% | +20.3% |
| Q4 2021 | $6,961,000 | -7.7% | 351,576 | -8.2% | 0.30% | -15.0% |
| Q3 2021 | $7,541,000 | -11.3% | 383,176 | -0.9% | 0.35% | -10.6% |
| Q2 2021 | $8,506,000 | -5.4% | 386,608 | +2.3% | 0.40% | -10.6% |
| Q1 2021 | $8,989,000 | -6.6% | 377,827 | +2.7% | 0.44% | -16.1% |
| Q4 2020 | $9,627,000 | +59.7% | 368,031 | +6.2% | 0.53% | +41.2% |
| Q3 2020 | $6,030,000 | +34.4% | 346,458 | +29.9% | 0.37% | +28.5% |
| Q2 2020 | $4,488,000 | – | 266,809 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INGALLS & SNYDER LLC | 6,825,262 | $138,621 | 7.54% |
| Novo Holdings A/S | 3,377,768 | $68,602,468 | 4.28% |
| Parallel Advisors, LLC | 3,724,664 | $75,647,926 | 3.28% |
| TANAKA CAPITAL MANAGEMENT INC | 35,539 | $722 | 2.29% |
| Quantedge Capital Pte Ltd | 251,312 | $5,104,147 | 1.71% |
| S&T BANK/PA | 346,306 | $7,033 | 1.30% |
| Freshford Capital Management, LLC | 249,000 | $5,057,190 | 1.09% |
| Birchview Capital, LP | 50,000 | $1,016 | 0.72% |
| FAS Wealth Partners, Inc. | 306,276 | $6,220,466 | 0.70% |
| Bridge City Capital, LLC | 60,824 | $1,235 | 0.63% |